TEM vs RXRX
TEM and RXRX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | TEMTempus AI, Inc. | RXRXRECURSION PHARMACEUTICALS, INC. |
|---|---|---|
| Market cap | $8.07M | — |
| P/B | 0.02 | — |
| P/S | 0.0x | — |
| Revenue | $1.43B(TTM) | — |
| Revenue growth (YoY) | 83.4% | 26.9% |
| Net income | -$254.40M(TTM) | — |
| Earnings growth (YoY) | 65.3% | -39.1% |
| EPS, diluted | $-1.44(TTM) | — |
| EBIT margin | -19.9% | -867.9% |
| ROE | -55.1% | -62.9% |
| ROIC | — | -174.7% |
| 1y total return | -25.7% | -48.4% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: TEM vs RXRX
| Metric | TEM | RXRX |
|---|---|---|
| End value | $11.0K | $3.3K |
| Total return | +10.0% | -67.2% |
| CAGR | +4.6% | -40.8% |
| Volatility | 97.1% | 83.2% |
| Sharpe | 0.48 | -0.27 |
| Sortino | 0.76 | -0.41 |
| Max drawdown | -59.8% | -73.9% |
Based on 532 common trading days, 2024-06-14 → 2026-07-30 · risk-free 3.82% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)